Literature DB >> 6319793

Histologic and cell surface antigen studies of hematopoietic tumors induced by Cas-Br-M murine leukemia virus.

T N Fredrickson, W Y Langdon, P M Hoffman, J W Hartley, H C Morse.   

Abstract

Cas-Br-M, a cloned ecotropic murine leukemia virus (MuLV) of wild mouse origin that induces both neurogenic hindlimb paralysis and lymphomas, was injected into NFS/N inbred mice neonatally. Then the mice were observed for the development of neurologic disease and tumors. All mice manifested neurologic abnormalities by 6 months of age, and 58% of the animals died with hematopoietic neoplasms. The tumors included T- and B-cell lymphomas, lymphoblastic lymphoma, erythroleukemias, myelogenous leukemias, and a megakaryocytic leukemia. Cas-Br-M thus appeared to be unique among ecotropic MuLV in inducing a wide spectrum of hematopoietic tumors.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6319793

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


  18 in total

1.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

2.  Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.

Authors:  Margret S Fernandes; Mamatha M Reddy; Nicole J Croteau; Christoph Walz; Henry Weisbach; Klaus Podar; Hamid Band; Martin Carroll; Andreas Reiter; Richard A Larson; Ravi Salgia; James D Griffin; Martin Sattler
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

3.  v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas.

Authors:  W Y Langdon; J W Hartley; S P Klinken; S K Ruscetti; H C Morse
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Infection of immune mast cells by Harvey sarcoma virus: immortalization without loss of requirement for interleukin-3.

Authors:  A Rein; J Keller; A M Schultz; K L Holmes; R Medicus; J N Ihle
Journal:  Mol Cell Biol       Date:  1985-09       Impact factor: 4.272

5.  Recombinant murine retroviruses containing avian v-myc induce a wide spectrum of neoplasms in newborn mice.

Authors:  H C Morse; J W Hartley; T N Fredrickson; R A Yetter; C Majumdar; J L Cleveland; U R Rapp
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

6.  Susceptibility to raf and raf/myc retroviruses is governed by different genetic loci.

Authors:  S P Klinken; J W Hartley; T N Fredrickson; U R Rapp; H C Morse
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas.

Authors:  W L Vasmel; M Zijlstra; T Radaszkiewicz; C J Leupers; R E de Goede; C J Melief
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Identification of a common viral integration region in Cas-Br-E murine leukemia virus-induced non-T-, non-B-cell lymphomas.

Authors:  D Bergeron; L Poliquin; C A Kozak; E Rassart
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Retrovirus-induced spongiform encephalopathy: the 3'-end long terminal repeat-containing viral sequences influence the incidence of the disease and the specificity of the neurological syndrome.

Authors:  L DesGroseillers; E Rassart; Y Robitaille; P Jolicoeur
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Rapid induction of hemopoietic neoplasms in newborn mice by a raf(mil)/myc recombinant murine retrovirus.

Authors:  U R Rapp; J L Cleveland; T N Fredrickson; K L Holmes; H C Morse; H W Jansen; T Patschinsky; K Bister
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.